Johnson & Johnson (J&J) announced that a combination of its lung cancer drugs, Rybrevant and Lazcluze, extended survival by at least a year compared to AstraZeneca's Tagrisso in a clinical trial. J&J aims to challenge Tagrisso's dominance as a leading treatment for non-small cell lung cancer with EGFR mutations.
Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial .
J&J is trying to supplant AstraZeneca's blockbuster Tagrisso, a once-daily pill that has transformed the treatment of non-small cell lung cancer with EGFR mutations and extended the median survival to about three years. These genetic errors cause cancer cells to proliferate. They're responsible for between 10% and 15% of lung cancer cases in the U.S., according to theJ&J executives hailed the result as a game-changer that should change the treatment of this type of lung cancer.
Lung Cancer Drugs Clinical Trial Rybrevant Lazcluze Tagrisso Survival
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Johnson & Johnson's Lung Cancer Drugs Show Longer Survival Than AstraZeneca's TagrissoA clinical trial shows J&J's combination therapy extending survival for at least a year longer than Tagrisso. This breakthrough could change the treatment landscape for non-small cell lung cancer with EGFR mutations.
Read more »
J&J's Lung Cancer Drug Combo Shows Survival Advantage Over AstraZeneca's TagrissoA combination of Johnson & Johnson's lung cancer drugs, Rybrevant and Lazcluze, has demonstrated a statistically significant improvement in survival compared to AstraZeneca's Tagrisso in a clinical trial.
Read more »
FDA Approves Drug for Aggressive Small-Cell Lung CancerThe FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same time.
Read more »
How your scented Christmas candles can up your risk of heart disease, lung cancerCan burning scented candles spark health issues?
Read more »
BioNTech's Lung Cancer Vaccine Enters Phase I TrialsBioNTech's BNT116 vaccine, designed to treat non-small cell lung cancer (NSCLC), is undergoing phase I trials. The mRNA-based vaccine aims to enhance the immune system's response to lung cancer cells, potentially improving survival rates and preventing recurrence.
Read more »
Home-Based Exercise Program Improves Exercise Capacity and Quality of Life in Lung Cancer SurvivorsA new study has found that while a home-based exercise program did not significantly improve self-reported physical function in lung cancer survivors after surgery, it did enhance exercise capacity, health-related quality of life, and exercise self-efficacy.
Read more »